Written By: Pharmacally Medical News Desk
Pfizer has officially completed the acquisition of Metsera, a biotechnology company known for its next-generation GLP-1 and amylin-based obesity and cardiometabolic drug candidates. The deal, valued at approximately $7 billion with potential milestones pushing it to $10 billion, marks a major strategic expansion for Pfizer into the rapidly growing obesity treatment market. This acquisition follows an intense bidding war between Pfizer and Novo Nordisk, highlighting the high stakes surrounding innovations in the GLP-1 therapeutic area.
The acquisition agreement was finalized at a purchase price of $65.60 per share in cash. Pfizer now wholly owns Metsera, gaining full rights to Metsera’s promising pipeline including MET-097i a long-acting GLP-1 receptor agonist designed for monthly or weekly dosing and other early-stage assets like a novel oral GLP-1 and an amylin analog. This portfolio is expected to complement Pfizer’s existing metabolic disease franchise and fortify its position in the obesity management market.
Pfizer first announced its intent to acquire Metsera in September 2025. After multiple rounds of bidding and negotiations, Pfizer officially closed the deal in mid-November 2025. Following regulatory approvals and shareholder consent, Metsera’s shares have been delisted from the NASDAQ, formally transitioning the company into Pfizer’s global development pipeline.
The acquisition was preceded by a highly publicized bidding war with Novo Nordisk, the current market leader in GLP-1 therapies. Novo initially made an aggressive offer to acquire Metsera, which prompted Pfizer to raise its bid, ultimately winning the deal. This contest underscored the critical importance of Metsera’s pipeline in the increasingly crowded and competitive GLP-1 market, as both companies contend to maintain or capture leading market positions in obesity and diabetes treatment.
Pfizer plans to accelerate the clinical development of Metsera’s candidates, targeting a Phase 3 launch for MET-097i and advancing other pipeline drugs towards approval. Leveraging Pfizer’s global commercial and manufacturing scale, the company aims to optimize the delivery and accessibility of this novel therapeutics, addressing the global obesity epidemic with innovative treatment options that offer improved dosing convenience and efficacy.
Table: Metsera Assets Added to Pfizer’s Pipeline
Candidate Name | Mechanism/Type | Development Stage | Key Features |
MET-097i | GLP-1 (injectable) | Entering Phase 3 | Weekly/monthly dosing |
MET-233i | Amylin Analog | Phase 1 | Monotherapy/combo potential |
Oral GLP-1 | GLP-1 (oral) | Phase 1 | Oral dosing convenience |
As part of the acquisition, Pfizer gains all intellectual property, regulatory filings, clinical trial data, and manufacturing capabilities associated with Metsera’s pipeline. This includes exclusive rights to MET-097i and related compounds, ongoing research programs, and preclinical development assets, as well as the talent and expertise embedded within Metsera’s scientific and development teams.
“This acquisition milestone goes beyond a mere business transaction it signifies a purposeful investment in the future landscape of healthcare. By bringing Metsera under our wing, we are channeling our resources into one of the most transformative and fastest-growing therapeutic areas, setting ourselves up to be leaders in defining its future. We are eager to integrate Metsera’s innovative drug portfolio with Pfizer’s expansive global development, manufacturing, and commercial capabilities. Collaborating with the talented teams from Metsera, we share a unified mission to expedite the advancement and global delivery of these promising candidate therapies to patients in need,” said Albert Bourla, Pfizer Chairman and Chief Executive Officer.
References
Pfizer Completes Acquisition of Metsera, 13 November 2025, Pfizer, https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-metsera
Pfizer completes $10bn acquisition of Metsera to kickstart its GLP-1 goals, Manufacturing chemist, 14 November 2025, https://manufacturingchemist.com/pfizer-completes-10bn-acquisition-of-metsera-glp-1
Pfizer completes up to $10 billion acquisition of Metsera, 13 November 2025, Reuters, https://www.reuters.com/legal/transactional/metsera-shareholders-vote-10-billion-acquisition-by-pfizer-2025-11-13/,
Pfizer closes $10 billion Metsera deal, 14 November 2025, Stat10, https://www.statnews.com/2025/11/14/biotech-news-pfizer-closes-metsera-deal/